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Macleod and Hickman (1) focus on the relationships between cannabis and schizophrenia and 
dismiss research examining the linkages between cannabis and symptom measures on the grounds 
that the linkage between symptom levels and clinical outcomes is not known. While this focus 
favours the arguments they develop, it does not adequately represent the literature that they claim to 
be reviewing. The focus of this literature has not been on the specific linkages between cannabis 
and schizophrenia, but rather on whether the use of cannabis increases rates of psychotic symptoms 
(2). 
Macleod and Hickman propose that any link between cannabis use and psychotic symptoms 
could be explained by residual confounding or reverse causation. Because of their focus on 
schizophrenia, they minimise recent research that has examined these issues using symptom 
measures. This evidence has been examined in a number of recent reviews (2-8) all of which have 
concluded that the weight of the evidence favours the view that the associations between cannabis 
and increased rates of psychotic symptoms are likely to be causal.  Perhaps the most comprehensive 
review of this evidence is provided by Moore et al (4), who noted that that the findings of 
associations between cannabis and psychotic symptoms have been replicated by a series of  7 cohort 
studies in which: a) about 60 confounding factors have been controlled; b) one study controlled 
non-observed confounding; and c) in all studies reverse causality had been controlled. All studies 
produced evidence consistent with the view that there is a modest association between increasing 
use of cannabis and increased rates of psychotic symptoms.  Further, as Hall has pointed out (3),  
these findings are supported by these additional lines of evidence: laboratory findings in animals; 
double-blind provocation research with people with schizophrenia; and by evidence of gene x 
environment interactions. 
Although all of this evidence could be dismissed on the grounds of inappropriate 
measurement, failure to control residual confounding and reverse causality, such arguments are 
neither parsimonious nor compelling.  In order to sustain their position that cannabis may not be 
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causally to related to psychosis/psychotic symptoms, Macleod and Hickman have to engage in a 
increasingly elaborate set of arguments which: a) focus the debate exclusively on schizophrenia 
rather than psychotic symptoms; b) dismiss recent studies that have extensively controlled 
confounding and reverse causality; and c) discount evidence of underlying biological mechanisms. 
As Macleod and Hickman note, their arguments are largely underwritten by analogy with “several 
recent studies much more methodologically robust than those relating to cannabis use to psychosis, 
which have led to some of the most important mistakes in recent epidemiological history”.  The 
issue to which they refer concerns the discrepancies between observational studies and randomised 
trial findings in the area of hormone replacement therapy (HRT) (9). In that area, observational 
studies suggested positive benefits in reducing coronary heart disease, whereas randomised control 
trials led to the opposite conclusion.  Here is not the place to review this literature, but two points 
are worth making. The first is that the discrepancy between randomised controlled trials and 
observational studies for the HRT and CHD was an exception to the general rule that the 
conclusions of observational studies have been found to be consistent with RCTs (10, 11).  Second, 
an examination of the reasons for observational studies of HRT producing misleading findings 
appears to have been due to a failure to adequately control socio-economic factors (9). These 
limitations in the assessment of confounders do not apply to the literature on cannabis and psychotic 
symptoms. 
In summary, while it remains possible that associations between cannabis and psychotic 
symptoms are non-causal and can be explained away as a result of inadequate measurement, 
residual confounding and reverse causation, the weight of the evidence including observational 
research, animal studies, laboratory research and behavioural genetic research all points to a causal 
process in which increasing use of cannabis is associated with small but detectable increases in the 
risks of psychosis and psychotic symptoms.  While the HRT example posts a warning about the 
pitfalls of causal reasoning with observational evidence, this example is, in fact, an exception to the 
general rule that the findings of well-conducted observational research are usually consistent with 
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the findings of well-conducted randomised trials.  Despite Macleod and Hickman’s reservations, a 
growing number of well-conducted observational studies suggest the presence of a causal link 
between increasing use of cannabis and increasing rates of psychosis/psychotic symptoms.  
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